Cell therapy is a treatment involving the genetic modification and reprogramming of a patient’s immune cells to target their own specific cancer, making it a truly individualised medicine. It’s one of the most promising – and one of the most complex – cancer treatments available today.
As one of the leaders in cell therapy with a sole focus on advancing CAR T treatments in cancer, Kite, a Gilead Company, works to develop cell therapies with the potential to address the needs of people with advanced, or unresponsive, haematological cancers who have few remaining treatment options. But we can’t – and don’t – do this alone.
